The Androtriol Injection for the Treatment of Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

Also called NCT06679322

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06679322
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06679322. Randomized; quadruple masking; primary purpose treatment. Start 2024-10-31 (anticipated); primary completion 2025-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Androtriol Injection for the Treatment of Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Androtriol Injection (High-dose group)
Intervention (Drug)
Androtriol Injection (Low-dose group)
Intervention (Drug)
Hydroxypropyl-β-cyclodextrin injection
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct06679322
Content hash
6b65aabe92a6c718a39a60ca1e4ed41a6d7524f1cf8d848fe058d6e34d334e2f